CL vs KPTI · P/E 34, rev $10.69B vs rev $68.5M
Colgate-Palmolive Company (CL) versus Karyopharm Therapeutics Inc (KPTI) — a side-by-side from cached financials, not a winner call.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
Latest reported CL revenue for 2026-06-30 was $10.69B. Net income was $1.34B. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
CL currently screens at market cap $70.88B and trailing P/E 34.3. KPTI currently screens at market cap $205.6M.
Not investment advice. Open the CL and KPTI stock pages for the full models.
Not investment advice.